Oncoinvent

Historical price data

Oncoinvent's mission is to transform cancer care through targeted alpha-particle therapy, specifically for cancers that spread to body cavities. Its core achievement is the development of Radspherin, a first-in-class intraperitoneal alpha-emitting radiopharmaceutical currently in Phase 2 clinical trials. The company's strategy leverages the deep radiopharma expertise of its founders—inventors of the approved drug Xofigo®—and an integrated in-house manufacturing capability to advance its pipeline and establish a new treatment paradigm for regional metastatic disease.

Proprietary platform using biodegradable calcium carbonate microparticles to deliver alpha-emitting radionuclides (e.g., radium-224) for targeted, regional radiation therapy within body cavities.

Oncoinvent's primary competition is the current standard of care, Hyperthermic Intraperitoneal Chemotherapy (HIPEC). In radiopharma, it faces indirect competition from companies developing systemic targeted alpha therapies, but its intra-cavitary microparticle approach is highly differentiated with no direct late-stage analogues.